NCT00785291
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients with HER2+ breast cancer must have had prior Herceptin/trastuzumab or Tykerb/lapatinib
Exclusions: Patients with prior chemotherapy for metastatic breast cancer; Patients with unstable untreated central nervous system (CNS) metastases or leptomeningeal disease
https://clinicaltrials.gov/show/NCT00785291